Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial-Reference-Cited by-同舟云学术

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

Published:2018-04 Issue:4 Volume:29 Page:1056-1062
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Buisseret L.^ORCID,Pommey S.,Allard B.,Garaud S.,Bergeron M.,Cousineau I.,Ameye L.,Bareche Y.,Paesmans M.,Crown J.P.A.,Di Leo A.,Loi S.,Piccart-Gebhart M.,Willard-Gallo K.,Sotiriou C.,Stagg J.

Funder

Canadian Institutes of Health Research

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/4/1056/25082449/mdx730.pdf

Reference26 articles.

1. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer;Luen;Pathology,2017

2. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013;Goldhirsch;Ann Oncol,2013

3. Triple-negative breast cancer: clinical features and patterns of recurrence;Dent;Clin Cancer Res,2007

4. Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting;García-Teijido;Clin Med Insights Oncol,2016

5. Anti-CD73 immunotherapy: a viable way to reprogram the tumor microenvironment;Antonioli;Oncoimmunology,2016

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Boost Infiltration and Activity of T Cells via Inhibiting Ecto-5′-nucleotidase (CD73) Immune Checkpoint to Enhance Glioblastoma Immunotherapy;ACS Nano;2024-08-16

2. A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus;Frontiers in Immunology;2024-08-12

3. The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients;Pathology - Research and Practice;2024-08

4. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer;Future Oncology;2024-07-18

5. Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer;Cancer Medicine;2024-07